Key Takeaway: The article discusses the long-term outcomes of Arimoclomol for treating Niemann-Pick disease type C (NPC) in a real-world setting, based on data from an expanded access program in the USA. The findings will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium. The results suggest that Arimoclomol may provide significant benefits for NPC patients.
Price reaction · baseline $7.19 (2024-09-04 close) · hit pre-market · 1 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promise for treating NPC in real-world settings.
Long-term outcomes indicate potential benefits for patients.
Expanded access program highlights commitment to patient care.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol for the Treatment of NPC in a Real-World Setting: Long-Term Outcomes from an Expanded Access Program in the USA
Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium - 09/06/2024
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used for treating Niemann-Pick disease type C (NPC).
What were the outcomes of the expanded access program?
The program indicated promising long-term outcomes for NPC patients using Arimoclomol.
When will the findings be presented?
The findings will be presented at the SSIEM 2024 Annual Symposium.
What is the significance of the study?
The study highlights the potential benefits of Arimoclomol in real-world settings for NPC.